CCRM Corporate Video
FollowMore Content From CCRM Corporate Video
-
Understanding Cryopreservation of Cellular Therapies
Cryopreservation is the process of using ultra-low temperatures to preserve living cells and tissues for a prolonged time period. In a typical immunotherapy commercial manufacturing workflow, cells may be selectively isolated from peripheral blood…Company Blog Released on 02.13.2020
-
Animal component free (ACF) media development for cell therapies
ACF media achieved comparable performance to serum containingCase Studies Released on 02.01.2020
-
Induced Pluripotent Stem Cells in Cell and Gene Therapy – Part 1: Understanding Reprogramming
What is an Induced Pluripotent Stem Cell? Stemming (pun intended) from the fundamental question in developmental biology around whether cellular differentiation could be reversed – like many transformative scientific discoveries – iden…Company Blog Released on 01.29.2020
-
New project to advance platelet-based therapeutics for patients
CCRM and GE Healthcare Life Sciences develop proprietary media formulations for Platelet BioGenesisNews Releases Released on 01.28.2020
-
THE CENTRE FOR CELL AND VECTOR PRODUCTION (CCVP)
A Transparent and Flexible Approach to ManufacturingLiterature / Brochures Released on 01.23.2020
-
Process Development for Scaled-up hESC/hiPSC Manufacturing
An optimized 14-day manufacturing workflow which produces > 10^10 , cells was developed in < 12 monthsCase Studies Released on 01.15.2020
-
Innovative Development and Manufacturing Services
For Global Cell and Gene Therapy LeadersinLiterature / Brochures Released on 01.10.2020
-
Road to success: Understanding Good Laboratory Practice for cell and gene therapies
Good Laboratory Practice (GLP) studies are essential for generating nonclinical study data supporting drug product submissions or applications for human use. According to the most basic definition, GLP is a set of principles that can be applied to en…Company Blog Released on 01.10.2020
-
Industrializing Autologous Adoptive Immunotherapies: Manufacturing Advances and Challenges
Cell therapy has proven to be a burgeoning field of investigation, evidenced by hundreds of clinical trials being conducted worldwide across a variety of cell types and indications. Many cell therapies have been shown to be efficacious in humans, suc…White Papers / Tech Papers Released on 12.11.2019
-
Commercial Scale Manufacturing of Allogeneic Cell Therapy
Allogeneic cell therapy products are generating encouraging clinical and pre-clinical results. Pluripotent stem cell (PSC) derived therapies, in particular, have substantial momentum and the potential to serve as treatments for a wide range of indica…White Papers / Tech Papers Released on 12.11.2019
-
What Are the Benefits of an Automated High-Throughput Screening Process for Custom Cell Culture Media Development
We are often asked if culture media development can be customized at the discovery stage of the product, and if feasible, how it can be done.Company Blog Released on 11.21.2019
-
Notch Therapeutics – a new company with a revolutionary allogeneic T cell technology
(“off the shelf”)News Releases Released on 11.04.2019
-
Planning Is Everything - Quality Control Testing in Cell and Gene Therapy
Compliance with quality control (QC) standards is a basic requirement for products manufactured under good manufacturing practices (GMP) conditions. In this post we will explore the main compendial QC tests that ensure cell and gene therapies are saf…Company Blog Released on 10.30.2019
-
How To Scale-Up Lentiviral Vector Production Part 2: Considerations for Downstream Processing
In Part 1 of our series on LVV manufacturing we covered scale-up of upstream processing steps. In this post we will look at the key steps in DSP. The industry “gold-standard” for recovery of purified and concentrated LVV is 10-20 percent.…Company Blog Released on 10.30.2019
-
Considerations for the Use of Stable Producer Lines in the Manufacturing of Lentiviral Vectors
In an introductory post on lentiviral vector (LVV) manufacturing for cell and gene therapies (CGTs) we touched upon the challenges with transfection-based protocols for producing LVVs at large scale. Here we will take a closer look at the use of stab…Company Blog Released on 10.30.2019
